GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Short Interest

PCI Biotech Holding ASA (FRA:4QG) Short Interest


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of PCI Biotech Holding ASA's Short Interest

For the Biotechnology subindustry, PCI Biotech Holding ASA's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Short Interest distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Short Interest falls into.


PCI Biotech Holding ASA (FRA:4QG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Short Interest
Comparable Companies
OSL:ABTEC OSL:SOFTX OSL:CRNA OSL:ABS OSL:LYTIX OSL:TRMED OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB
Traded in Other Exchanges
PCIB:Norway
Address
Ullernchausseen 64, Oslo, NOR, N-0379
Website
https://www.pcibiotech.com
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (FRA:4QG) Headlines

No Headlines